Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Boston Common Asset Management LLC

Boston Common Asset Management LLC grew its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 25.3% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 27,343 shares of the biopharmaceutical company's stock after purchasing an additional 5,525 shares during the period. Boston Common Asset Management LLC's holdings in Regeneron Pharmaceuticals were worth $17,342,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of REGN. Pinney & Scofield Inc. acquired a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth about $25,000. OFI Invest Asset Management acquired a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth about $28,000. Rakuten Securities Inc. grew its position in shares of Regeneron Pharmaceuticals by 62.5% during the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock worth $28,000 after buying an additional 15 shares in the last quarter. Avalon Trust Co acquired a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth about $36,000. Finally, Crowley Wealth Management Inc. acquired a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth about $36,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock traded down $112.15 during trading hours on Friday, hitting $493.24. The stock had a trading volume of 6,307,887 shares, compared to its average volume of 829,463. The firm has a market capitalization of $53.25 billion, a PE ratio of 12.89, a PEG ratio of 2.34 and a beta of 0.43. Regeneron Pharmaceuticals, Inc. has a twelve month low of $485.00 and a twelve month high of $1,211.20. The stock's 50 day moving average is $584.25 and its 200 day moving average is $666.47. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing the consensus estimate of $8.83 by ($0.61). The firm had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. Regeneron Pharmaceuticals's revenue was down 3.7% compared to the same quarter last year. During the same period in the previous year, the company posted $9.55 earnings per share. As a group, research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Tuesday, May 20th will be issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.71%. The ex-dividend date is Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio is presently 8.96%.

Analysts Set New Price Targets

REGN has been the subject of a number of analyst reports. Royal Bank of Canada downgraded Regeneron Pharmaceuticals from a "moderate buy" rating to a "hold" rating and set a $662.00 price objective for the company. in a research report on Friday. The Goldman Sachs Group lowered their price objective on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating for the company in a research report on Wednesday, April 30th. Citigroup raised Regeneron Pharmaceuticals from a "neutral" rating to a "buy" rating and upped their price target for the company from $600.00 to $700.00 in a report on Wednesday, May 14th. Bernstein Bank lowered their price target on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a report on Tuesday, February 4th. Finally, Guggenheim reaffirmed a "buy" rating on shares of Regeneron Pharmaceuticals in a report on Friday. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have issued a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $874.56.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.